Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
NeoplasmsBone Diseases
Interventions
DRUG

Radium Ra 223 dichloride (Xofigo, BAY88-8223)

50 kBq/kg intravenous injection once every 4 weeks, will be administrated from cycle 2 up to 6 cycles

DRUG

paclitaxel

90 mg/m2 intravenous injection per week in a 3-week-on / 1-week-off regimen, will be administered as per local standard of care, starting in cycle 1

Trial Locations (5)

3109601

Haifa

6423906

Tel Aviv

00029

HUS

SM2 5PT

Sutton

S10 2SJ

Sheffield

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY